Abbott Laboratories
NYSE:ABT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abbott Laboratories
Stock-Based Compensation
Abbott Laboratories
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Abbott Laboratories
NYSE:ABT
|
Stock-Based Compensation
$664m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Stock-Based Compensation
$299m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Stock-Based Compensation
$158.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Stryker Corp
NYSE:SYK
|
Stock-Based Compensation
$243m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Stock-Based Compensation
$60m
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Stock-Based Compensation
$788.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
See Also
What is Abbott Laboratories's Stock-Based Compensation?
Stock-Based Compensation
664m
USD
Based on the financial report for Mar 31, 2026, Abbott Laboratories's Stock-Based Compensation amounts to 664m USD.
What is Abbott Laboratories's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
8%
Over the last year, the Stock-Based Compensation growth was 1%.